Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A; INOVATYON study group. Colombo N, et al. Among authors: nyvang gb. Br J Cancer. 2023 Apr;128(8):1503-1513. doi: 10.1038/s41416-022-02108-7. Epub 2023 Feb 9. Br J Cancer. 2023. PMID: 36759720 Free PMC article. Clinical Trial.
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR, Åvall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, Ør Knudsen A, Staff S, Krog Vistisen A, Bjørge L, Mäenpää JU; AVANOVA investigators. Mirza MR, et al. Among authors: nyvang gb. Lancet Oncol. 2019 Oct;20(10):1409-1419. doi: 10.1016/S1470-2045(19)30515-7. Epub 2019 Aug 29. Lancet Oncol. 2019. PMID: 31474354 Clinical Trial.
Beyond HRD status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer.
Kjeldsen MK, Jørgensen M, Grønseth DSB, Schønemann-Lund M, Nyvang GB, Haslund CA, Knudsen AO, Motavaf AK, Malander S, Anttila M, Lindahl G, Mäenpää J, Dimoula M, Werner TL, Iversen TZ, Hietanen S, Fokdal L, Dahlstrand H, Bjorge L, Birrer MJ, Mirza MR, Rossing M. Kjeldsen MK, et al. Among authors: nyvang gb. Cancer Res Commun. 2024 Nov 26. doi: 10.1158/2767-9764.CRC-24-0294. Online ahead of print. Cancer Res Commun. 2024. PMID: 39591206 Free article.
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.
Mirza MR, Bjørge L, Marmé F, Christensen RD, Gil-Martin M, Auranen A, Ataseven B, Rubio MJ, Salutari V, Luczak AA, Runnebaum IB, Redondo A, Lindemann K, Trillsch F, Ginesta MPB, Roed H, Kurtz JE, Petersson KS, Nyvang GB, Sehouli J. Mirza MR, et al. Among authors: nyvang gb. Gynecol Oncol. 2024 Dec 9;192:128-136. doi: 10.1016/j.ygyno.2024.12.003. Online ahead of print. Gynecol Oncol. 2024. PMID: 39657575 Free article.
Trends in gynecologic cancer among elderly women in Denmark, 1980-2012.
Ør Knudsen A, Schledermann D, Nyvang GB, Mogensen O, Herrstedt J; Academy of Geriatric Cancer Research (AgeCare). Ør Knudsen A, et al. Among authors: nyvang gb. Acta Oncol. 2016;55 Suppl 1:65-73. doi: 10.3109/0284186X.2015.1115119. Epub 2016 Jan 19. Acta Oncol. 2016. PMID: 26784001